FGEN: FibroGen Inc Price-to-Sales Ratio

Corporate company logo of FibroGen Corp (FGEN)

A liquidity crisis and the threat of bankruptcy due to failed trials place FibroGen, Inc. (FGEN) in a precarious position. The price/sales multiple illustrates this instability, where 4.70 captures the current state of the parameter. The firm's survival relies on royalties from Asia amid collapsed pricing power, while its primary earnings are based on roxadustat sales through strategic partners.

fibrogen.com (FGEN): P/S Multiple from 07/04/2022 to 01/08/2026

Metric breakdowns and analytics for FibroGen Corp (FGEN)

- share price and consensus valuation forecast:
Price Performance Chart fibrogen.com|FGEN - Analyst Consensus Forecast
- market capitalization information:
Market Valuation FibroGen Corp|FGEN - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share FibroGen|FGEN - Book Capitalization|Market Value to Book Value Ratio fibrogen.com|FGEN - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio FibroGen, Inc.|FGEN - Long-Term Debt to Equity|Current Liabilities to Capital FibroGen Corporation|FGEN - Company Aggregate Debts|Debt to Net Assets FibroGen Corp|FGEN - Company Long-Term Debts|Short-Term Debt FibroGen|Immediate Liquidity Ratio fibrogen.com
- net income and valuation ratios data:
FGEN - Net Income|Expected Net Income FibroGen, Inc.|FGEN - P/E Multiple|Market Cap to Projected Earnings FibroGen Inc|FGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation FibroGen Corp|FGEN - Operating profit EBITDA|Net earnings per share for the last 12 months FibroGen|FGEN - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months fibrogen.com|FGEN - Earnings growth in current year|Net earnings per share change forecast for next year FibroGen, Inc.
- issuer revenue and sales details:
FGEN - Revenue and Sales Volume|Company Sales Forecast fibrogen.com|FGEN - P/S Multiple|Market Cap to Future Revenue Ratio FibroGen Corp
General company analysis:FibroGen, Inc.
Finished products of FibroGen

The P/S metric is critical for stress-testing assets and identifying overvalued companies, as it compares market capitalization to annual sales volume to demonstrate how much investors are willing to pay per unit of revenue. The current price/sales multiple for FibroGen, Inc. (FGEN) is 4.70. This chart confirms the resilience of FibroGen, Inc., whose biotechnological developments are shielded from macroeconomic shocks due to stable demand for innovative medicine.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|Jyong Biotech Corp - P/S Multiple|Price-to-Revenue Coefficient Ligand Corp LGND|AMRX: P/S Multiple|PRGO (perrigo.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alvotech SA|LQDA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP - Price to Sales|P/S Multiple MNKD (MannKind Corporation)|Price-to-Revenue Multiple amphastar.com|Pacira BioSciences, Inc. - P/S Multiple|Price to Sales ARS Pharmaceuticals Inc|Theravance (TBPH) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AQST|Market Cap to Revenue SCPH|TECX: Market Capitalization-to-Revenue Ratio|P/S Multiple TNXP|Price-to-Revenue Coefficient sxtchina.com|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST: Market Cap to Revenue Ratio|eXoZymes Inc - P/S Multiple|Oramed Pharmaceuticals (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|HYFT - Price-to-Revenue Coefficient|ABVC (ABVC BioPharma Inc) - P/S Multiple|Cumberland Corp - Price-to-Sales Ratio|P/S Multiple QNTM|telomirpharma.com (TELO) - Price-to-Revenue Multiple|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|Synergy CHC Corp. (SNYR) - Price to Sales|RLYB - Price-to-Revenue Ratio|LEXX (Lexaria Bioscience) - Market Cap to Revenue Ratio|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|Price-to-Sales Ratio PTHL (Pheton Holdings)|APM (Aptorum Group Ltd) - P/S Multiple|LYRA: Market Capitalization-to-Revenue Ratio|P/S Multiple IBO|P/S Multiple tnfpharma.com (TNFA)|Price-to-Revenue Ratio cbdMD YCBD|Market Capitalization-to-Revenue Ratio PRFX|CYTO - Price-to-Revenue Ratio|Lipella Pharmaceuticals Inc (LIPO) - Market Cap to Revenue|OPTN: P/S Multiple|Pieris Pharma (PIRS) - P/S Multiple|Market Cap to Revenue PROC|PTPI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN - Price to Sales|TFF Pharma - Market Cap to Revenue